Eurofins-Cerep SA
PAR:ALECR

Watchlist Manager
Eurofins-Cerep SA Logo
Eurofins-Cerep SA
PAR:ALECR
Watchlist
Price: 22 200 EUR 8.82%
Market Cap: 111m EUR

Eurofins-Cerep SA
Investor Relations

Eurofins-Cerep SA engages in providing preclinical drug research services. The company is headquartered in Celle-Levescault, Nouvelle-Aquitaine and currently employs 211 full-time employees. The company went IPO on 2010-03-19. The Company, using its BioPrint technology systems that analyzes pharmaceutical drugs on the market, those that have been withdrawn, and those that failed in the development stages, builds up predictive models of the potential of new drugs. These predictions are based on the drugs' chemical structure and their performance in vitro. The firm then offers solutions to the pharmaceutical and biotechnology sectors on reducing time and costs in the early stages of the drug development process. Clients can also gain access to some of the Company's technology by subscribing to BioPrint. In December 2013, it sold Cerep Inc, its American subsidiary, to Eurofins-Panlabs Inc, part of the Eurofins Scientific SE group.

Show more
Loading

Earnings Calls

No Earnings Calls Available

Management

Mr. Antoine Duthilleul
MD, Director & Pres of The Eurofins Discovery Products France
No Bio Available
Ms. Sophie Macault
Gen. Counsel & Corp. Sec.
No Bio Available

Contacts

Address
NOUVELLE-AQUITAINE
Celle-Levescault
Le Bois l'Eveque
Contacts
+33549893000
www.eurofins.fr